Glucagon-like peptide 1 analogues as adjunctive therapy for patients with type 1 diabetes: an updated systematic review and meta-analysis
As we mentioned earlier, glucagon is the management hormone for low energy states
Understanding how these medications affect the digestive system is essential for both clinicians and patients, as it provides context for managing potential side effects while maximizing therapeutic benefits for diabetes control and weight management
This advancement allows investigation of patient-specific disease mechanisms, therapeutic responses, and drug sensitivities ( (i) drug development process and (ii) precision medicine approach ( Drug Screening and Toxicology Testing
(American Diabetes Association, Arlington (VA)), 2021) R.Z
That said, because GLP-1 medications slow gastric emptying, fiber intake should be increased gradually and with adequate hydration